OA-451 Spirometry, diffusion capacity, absolute lung volumes and PET/CT findings upon completion of tuberculosis treatment – preliminary findings of StatinTB/ExtendTB trial

Résumé fourni par la source

Background Morbidity and mortality rates after successful completion of a six-month course of tuberculosis (TB) treatment remain elevated. Persistent lung inflammation (PLI) on 18F-FDG-PET/CT has been associated with TB relapse and may also lead to post-TB lung disease (PTLD). Methods The ongoing EDCTP-funded StatinTB trial (RIA2017T-2004; NCT04147286) evaluates safety/efficacy of 40 mg atorvastatin to reduce PLI after TB treatment in HIV-/HIV+ adults measured by 18F-FDG-PET/CT with extended total follow-up of 96 weeks (ExtendTB, NIH-funded). We report findings at time of enrolment into StatinTB/ExtendTB of the first 106 participants. Participants with clinical response to TB treatment and a negative sputum culture for TB at 16 weeks were screened after completing 24 weeks of treatment for drug-sensitive TB. Complete pulmonary function and PLI were measured using EasyOne Pro®Lab and PET/CT. PLI was defined as total lung glycolysis (TLG)≥50 SUVbw*mL. StatinTB/ExtendTB are conducted according to ICH-GCP. Results Of the 106 participants (32% women) aged 32.5±7.0 years who underwent PET/CT, 20.8% were HIV+, 57.5% smokers, 28.3% had previous TB; 13.2% reported ongoing cough, 3.8% chest pain and 8.5% shortness of breath. PLI was present in 49.1% of participants (mean TLG of 209±161 SUVbw*mL). Diffusing capacity of the lung for carbon monoxide (DLCO) was consistently reduced in participants with PLI (DLCO%Pred 73.4% vs. 93.7%; p=0.0002) as was FVC%Pred (82.1% vs. 94.9%; p=0.0004); FEV1%Pred was 82.1% vs 94.9%, p=0.0004. After accounting for other variables including HIV and smoking, every one percent increase in DLCO%Pred remained independently associated with a decrease of 4.7 SUVbw*mL of TLG (p=0.017). Conclusion PTLD is present in half of participants. Impaired DLCO is associated with PLI in adults after completing a 24-week treatment regimen for drug-sensitive TB. This highlights the need for treatment optimisation during and after TB treatment to reduce PTLD with persistent lung inflammation.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.